Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progress in gynecologic cancer.
Seiden MV. Seiden MV. Semin Oncol. 2009 Apr;36(2):90. doi: 10.1053/j.seminoncol.2008.12.010. Semin Oncol. 2009. PMID: 19332243 No abstract available.
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Gillet JP, et al. Among authors: seiden mv. Clin Cancer Res. 2012 Jun 1;18(11):3197-206. doi: 10.1158/1078-0432.CCR-12-0056. Epub 2012 Apr 5. Clin Cancer Res. 2012. PMID: 22492981 Free PMC article.
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC. Sarosy GA, et al. Among authors: seiden mv. Cancer. 2010 Mar 15;116(6):1476-84. doi: 10.1002/cncr.24861. Cancer. 2010. PMID: 20091841 Free PMC article. Clinical Trial.
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Krasner CN, et al. Gynecol Oncol. 2019 May;153(2):223-229. doi: 10.1016/j.ygyno.2019.02.004. Epub 2019 Feb 12. Gynecol Oncol. 2019. PMID: 30765148 Clinical Trial.
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Garcia-Carbonero R, et al. Among authors: seiden mv. J Clin Oncol. 2005 Aug 20;23(24):5484-92. doi: 10.1200/JCO.2005.05.028. J Clin Oncol. 2005. PMID: 16110008 Clinical Trial.
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Vasey PA, et al. Among authors: seiden mv. J Clin Oncol. 2002 Mar 15;20(6):1562-9. doi: 10.1200/JCO.2002.20.6.1562. J Clin Oncol. 2002. PMID: 11896105 Clinical Trial.
Clinical course of stage IV epithelial ovarian cancer.
Penson RT, Skates SJ, Fuller AJ Jr, Seiden MV. Penson RT, et al. Among authors: seiden mv. J Clin Oncol. 1999 Oct;17(10):3361-2. doi: 10.1200/JCO.1999.17.10.3361. J Clin Oncol. 1999. PMID: 10506641 No abstract available.
140 results